Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome - PubMed (original) (raw)
Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome
Paul Holvoet et al. JAMA. 2008.
Abstract
Context: Experimental data support the hypothesis that oxidized low-density lipoprotein (LDL) is associated with the metabolic syndrome. However, this hypothesis has not been tested in humans.
Objective: To establish the relation of oxidized LDL with metabolic syndrome in the general community.
Design, setting, and participants: The Coronary Artery Risk Development in Young Adults (CARDIA) study is a population-based, prospective, observational study. We studied 1889 participants who were between the ages of 18 and 30 years at the time of recruitment in 1985 and 1986 and living in 1 of 4 US metropolitan areas (41% African American; 56% women) and were seen both at year 15 (2000-2001, ages 33-45 years) and year 20 examinations (2005-2006).
Main outcome measure: The longitudinal association of oxidized LDL and incident metabolic syndrome. Oxidized LDL was measured with a monoclonal antibody-based enzyme-linked immunosorbent assay. The metabolic syndrome was defined according to the Adult Treatment Panel III of the National Cholesterol Education Program.
Results: Incident metabolic syndrome was diagnosed at the year 20 follow-up in 12.9% (243 of 1889) of participants who did not have metabolic syndrome at the 15-year follow-up. The odds ratios (ORs) for incident metabolic syndrome after 5 years' follow-up and adjusted for age, sex, race, study center, cigarette smoking, body mass index, physical activity, and LDL cholesterol levels by quintiles of oxidized LDL were 2.1 (95% confidence interval [CI], 1.1-3.8) for the second quintile (55.4-69.1 U/L); 2.4 (95% CI, 1.3-4.3) for the third quintile (69.2-81.2 U/L); 2.8 (95% CI, 1.5-5.1) for the fourth quintile (81.3-97.3 U/L); and 3.5 (95% CI, 1.9-6.6) for the fifth quintile (> or =97.4 U/L). The adjusted ORs for incidence of dichotomous components of metabolic syndrome in the highest vs the lowest quintile of oxidized LDL were 2.1 (95% CI, 1.2-3.6) for abdominal obesity, 2.4 (95% CI, 1.5-3.8) for high fasting glucose, and 2.1 (95% CI, 1.1-4.0) for high triglycerides. Low-density lipoprotein cholesterol was not associated with incident metabolic syndrome or with any of its components in the fully adjusted model containing oxidized LDL.
Conclusion: Higher concentration of oxidized LDL was associated with increased incidence of metabolic syndrome overall, as well as its components of abdominal obesity, hyperglycemia, and hypertriglyceridemia.
Figures
Figure. Study Flow Diagram
The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year 15 (2000–2001) for whom fresh frozen blood samples were available at year 15 for measuring plasma oxidized low-density lipoprotein and for whom all data were available at years 15 and 20 (2005–2006). aParticipants could be excluded for more than 1 reason.
Similar articles
- Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G. Onat A, et al. Atherosclerosis. 2003 May;168(1):81-9. doi: 10.1016/s0021-9150(03)00025-x. Atherosclerosis. 2003. PMID: 12732390 - Oxidized LDL Is Associated With Metabolic Syndrome Traits Independently of Central Obesity and Insulin Resistance.
Hurtado-Roca Y, Bueno H, Fernandez-Ortiz A, Ordovas JM, Ibañez B, Fuster V, Rodriguez-Artalejo F, Laclaustra M. Hurtado-Roca Y, et al. Diabetes. 2017 Feb;66(2):474-482. doi: 10.2337/db16-0933. Epub 2016 Dec 19. Diabetes. 2017. PMID: 27993926 - Longitudinal associations of high-density lipoprotein cholesterol or low-density lipoprotein cholesterol with metabolic syndrome in the Chinese population: a prospective cohort study.
Wang XR, Song GR, Li M, Sun HG, Fan YJ, Liu Y, Liu QG. Wang XR, et al. BMJ Open. 2018 May 9;8(5):e018659. doi: 10.1136/bmjopen-2017-018659. BMJ Open. 2018. PMID: 29743317 Free PMC article. - Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study.
Koskinen J, Magnussen CG, Würtz P, Soininen P, Kangas AJ, Viikari JS, Kähönen M, Loo BM, Jula A, Ahotupa M, Lehtimäki T, Ala-Korpela M, Juonala M, Raitakari OT. Koskinen J, et al. Eur J Prev Cardiol. 2012 Dec;19(6):1296-303. doi: 10.1177/1741826711425343. Epub 2011 Sep 29. Eur J Prev Cardiol. 2012. PMID: 21960651 - Oxidized LDL and coronary heart disease.
Holvoet P. Holvoet P. Acta Cardiol. 2004 Oct;59(5):479-84. doi: 10.2143/AC.59.5.2005219. Acta Cardiol. 2004. PMID: 15529550 Review.
Cited by
- Endothelial Dysfunction in Obesity and Therapeutic Targets.
Engin A. Engin A. Adv Exp Med Biol. 2024;1460:489-538. doi: 10.1007/978-3-031-63657-8_17. Adv Exp Med Biol. 2024. PMID: 39287863 Review. - Medical comorbidities in bipolar disorder (BIPCOM): clinical validation of risk factors and biomarkers to improve prevention and treatment. Study protocol.
de Girolamo G, Andreassen OA, Bauer M, Brambilla P, Calza S, Citerà N, Corcoy R, Fagiolini A, Garcia-Argibay M, Godin O, Klingler F, Kobayashi NF, Larsson H, Leboyer M, Matura S, Martinelli A, De la Peña-Arteaga V, Poli R, Reif A, Ritter P, Rødevand LN, Magno M, Caselani E; BIPCOM consortium. de Girolamo G, et al. Int J Bipolar Disord. 2024 May 4;12(1):15. doi: 10.1186/s40345-024-00337-8. Int J Bipolar Disord. 2024. PMID: 38703295 Free PMC article. - The association between inflammation, arterial stiffness, oxidized LDL and cardiovascular disease in Finnish men with metabolic syndrome - a 15-year follow-up study.
Saarinen HJ, Lahtela J, Mähönen P, Palomäki A; Hämeenlinna Metabolic Syndrome Research Program Study Group. Saarinen HJ, et al. BMC Cardiovasc Disord. 2024 Mar 15;24(1):162. doi: 10.1186/s12872-024-03818-x. BMC Cardiovasc Disord. 2024. PMID: 38491429 Free PMC article. - Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk.
Vekic J, Stromsnes K, Mazzalai S, Zeljkovic A, Rizzo M, Gambini J. Vekic J, et al. Biomedicines. 2023 Oct 26;11(11):2897. doi: 10.3390/biomedicines11112897. Biomedicines. 2023. PMID: 38001900 Free PMC article. Review. - Transitioning from having no metabolic abnormality nor obesity to metabolic impairment in a cohort of apparently healthy adults.
Ben-Assayag H, Brzezinski RY, Berliner S, Zeltser D, Shapira I, Rogowski O, Toker S, Eldor R, Shenhar-Tsarfaty S. Ben-Assayag H, et al. Cardiovasc Diabetol. 2023 Aug 26;22(1):226. doi: 10.1186/s12933-023-01954-w. Cardiovasc Diabetol. 2023. PMID: 37633936 Free PMC article.
References
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–689. - PubMed
- Trevisan M, Liu J, Bahsas FB, Menotti A Risk Factor and Life Expectancy Research Group. Syndrome X and mortality: a population-based study. Am J Epidemiol. 1998;148(10):958–966. - PubMed
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359. - PubMed
- Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955–1960. - PubMed
- Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360–370. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL053560/HL/NHLBI NIH HHS/United States
- N01-HC-48050/HC/NHLBI NIH HHS/United States
- N01HC95095/HL/NHLBI NIH HHS/United States
- 1R01-HL53560/HL/NHLBI NIH HHS/United States
- N01-HC-48049/HC/NHLBI NIH HHS/United States
- N01HC48050/HL/NHLBI NIH HHS/United States
- N01-HC-48048/HC/NHLBI NIH HHS/United States
- N01HC48048/HL/NHLBI NIH HHS/United States
- N01-HC-48047/HC/NHLBI NIH HHS/United States
- N01HC48049/HL/NHLBI NIH HHS/United States
- N01HC48047/HL/NHLBI NIH HHS/United States
- R01 HL053560-05/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical